Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
27(c) 25.6(c) 25.55(c) 25.4(c) 25.4 Last
530 164 612 663 484 440 429 387 509 976 Volume
+0.56% -5.19% -0.20% -0.59% 0.00% Change
More quotes
Financials ($)
Sales 2017 567 M
EBIT 2017 35,9 M
Net income 2017 6,72 M
Debt 2017 100 M
Yield 2017 -
Sales 2018 643 M
EBIT 2018 78,3 M
Net income 2018 40,8 M
Finance 2018 73,7 M
Yield 2018 -
P/E ratio 2017 2 540,00
P/E ratio 2018 28,78
EV / Sales2017 2,25x
EV / Sales2018 1,72x
Capitalization 1 179 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
03/23 ACORDA THERAPEUTICS : Launches Alexa Skill in Conjunction with MS Awareness Mont..
03/22 ACORDA THERAPEUTICS : Research Reports Initiation on Biotech Stocks -- Radius He..
03/16 ACORDA THERAPEUTICS : Patent Trials and Appeal Board PTAB Upholds Four AMPYRA® P..
03/13 ACORDA THERAPEUTICS : Alexa Skill Educates About MS As Part of MS Awareness Mont..
03/13 ACORDA THERAPEUTICS : Launches Alexa Skill in Conjunction with MS Awareness Mont..
03/09 ACORDA THERAPEUTICS : Study Results from Acorda Therapeutics Provide New Insight..
03/09 ACORDA THERAPEUTICS : to Present at the Cowen and Company 37th Annual Healthcare..
03/09 ACORDA THERAPEUTICS, INC. (NASDAQ : ACOR) Files An 8-K Other Events
03/09 ACORDA THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form ..
03/09 ACORDA THERAPEUTICS : Patent Trials and Appeal Board (PTAB) Upholds Four AMPYRA®..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03:56pGet the latest news and updates for $SLW $WX $GLW $TWX $ACOR automatically wi.. 
03/22Acorda Therapeutics : Research Reports Initiation on Biotech Stocks -- Radius.. 
03/20Acorda Therapeutics upgraded by Vetr Inc. to strong-buy. $30.58 PT.  
03/15Acorda Therapeutics upgraded by Vetr Inc. to strong-buy. $30.58 PT.  
03/13Benzinga's Top Upgrades, Downgrades For March 13, 2017  
More tweets
Qtime:18
News from SeekingAlpha
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/21 FDA OKs Newron's PD med Xadago
03/13 BIOTECH FORUM DAILY DIGEST : Gilead Facing Increasing Analyst Pressure, Spotligh..
03/13 Premarket analyst action - healthcare
03/10 Analyst action - healthcare
Advertisement
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Technical analysis trends ACORDA THERAPEUTI...
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 34,7 $
Spread / Average Target 36%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
David Lawrence Chief Financial & Accounting Officer
Andrew R. Blight Chief Scientific Officer
Anthony O. Caggiano Vice President-Research & Development
Richard P. Batycky Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS IN..35.11%1 179
AMGEN, INC.13.56%122 281
CELGENE CORPORATION6.45%95 861
GILEAD SCIENCES, INC.-5.75%88 214
REGENERON PHARMACEUTIC..-0.56%38 722
ACTELION LTD24.72%29 697
More Results